Related Experiment Video
Updated: Jan 13, 2026

08:29
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.5K
Neuropathologic Changes in People With Essential Tremor With Dementia: A Postmortem Study
Ethan Wainman1, Diane S Berry1, Nora C Hernandez1
1Department of Neurology, University of Texas Southwestern Medical Center, Dallas.
Neurology
|October 29, 2025
Summary
Alzheimer
Area of Science:
- Neuropathology
- Neurodegenerative Diseases
- Cognitive Impairment
Background:
- Essential tremor (ET) is associated with an increased risk of dementia.
- The underlying neuropathological reasons for this association are not fully understood.
- This study investigates the neuropathological features in individuals with ET and dementia.
Purpose of the Study:
- To elucidate the neuropathologic features associated with dementia in patients with essential tremor.
- To determine the extent to which Alzheimer's disease pathologies contribute to cognitive impairment in ET.
Main Methods:
- A 10-year prospective cohort study involving neuropsychological testing and cognitive diagnoses.
- Post-mortem neuropathological assessment of brains, including Braak stages, amyloid scores, and neuritic plaque scores.
- Statistical analysis to compare neuropathological findings across cognitive groups (normal cognition, MCI, dementia).
Main Results:
- Participants with ET-dementia showed significantly higher odds of severe Alzheimer's disease pathologies compared to those with normal cognition.
- Individuals with ET-mild cognitive impairment (MCI) exhibited intermediate neuropathological findings.
- Other neuropathologies were comparable across the cognitive groups.
Conclusions:
- Alzheimer's disease pathology is a primary contributor to cognitive impairment and dementia in essential tremor.
- Further research is needed to understand tau aggregation in ET and its relation to Alzheimer's disease.
- Findings suggest a potential link between ET and Alzheimer's disease, opening avenues for blood-based biomarker research.
Related Concept Videos
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806

